Jepsson and co-authors measured CSF levels of Aβ peptides (Aβ42, Aβ40, Aβ38), MCP-1, p-tau, t-tau, sAPPα, sAPPβ, and NfL in patients with PSP, CBD, PD, MSA, AD, FTD, NPH, and VaD and healthy controls [115]. This evidence concerns the gene MAPT and supranuclear palsy, progressive, 1.